Published in
Springer Nature [academic journals on nature.com], British Journal of Cancer, 5(123), p. 694-697, 2020
DOI: 10.1038/s41416-020-0948-x
Links
Tools
Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy
Journal article published in 2020 by
Kamal S. Saini 
,
Carlo Lanza,
Marco Romano,
Evandro de Azambuja,
Javier Cortes,
Begoña de las Heras,
Javier de Castro,
Monika Lamba Saini,
Sibylle Loibl,
Giuseppe Curigliano,
Chris Twelves,
Manuela Leone ,
Mrinal M. Patnaik
,
Carlo Lanza,
Marco Romano,
Evandro de Azambuja,
Javier Cortes,
Begoña de las Heras,
Javier de Castro,
Monika Lamba Saini,
Sibylle Loibl,
Giuseppe Curigliano,
Chris Twelves,
Manuela Leone ,
Mrinal M. Patnaik
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
SummaryThree cardinal manifestations of neoplasia, namely inflammation, immune dysfunction, and coagulopathy are also seen in patients with severe SARS-CoV-2 infection, providing a biological rationale for testing selected anticancer drugs for their ability to control the symptoms and/or modify the course of COVID-19.